微创医疗  MicroPort  
微创医疗器械（上海）有限公司， 由留美科学家常兆华博士创办于一九九八年五月，现已成为由Otsuka Pharmaceutical Corporation （大冢制药株式会社）、We'Tron Capital China Limited （中国微创投资管理有限公司）、SIIC MedTech Health Products Limited （上实医药健康产品有限公司）等投资的外商合资企业，主要从事各种高科技微创伤介入医疗产品的研究、制造、销售和服务，公司被认定为上海市高新技术企业。

公司的宗旨是“以人为本，在微创伤介入医学领域建设属于中华民族的世界级医疗集团”。公司研发中心被认定为上海市技术研发中心，吸纳了美国多位著名的生物医学工程界专家和介入医疗界科学家，拥有数十名包括博士、硕士在内的微创伤介入医疗器材产品开发与生产方面的专业人才，拥有药物支架包裹技术、颅内支架等数十项技术专利和多项独立知识产权，目前，正开发多种高科技微创伤介入治疗产品，并多个项目获国家、上海市、浦东新区多项科技基金的资助。

公司主要产品有冠脉药物支架系统、冠脉金属支架系统、颅内动脉支架系统、腹主动脉瘤和胸主动脉瘤等支撑型人造血管支架、球囊 (PTCA)扩张导管、导引导管及其相关附件、胰岛素泵、 射频消融电生理导管等医疗器械；它们中绝大多数填补国内空白，被认定为上海市高新技术成果转化项目，达国际先进水平，直接与国外产品竞争，已进入中国各大知名医院，并出口日本、欧洲、拉美等国家与地区，具有一定的品牌知名度和市场占有率。

公司始终以创建“一个属于医生和病人的品牌”为已任，高举民族工业的大旗，诚恳地希望与国内外各界人士精诚合作，共同努力，力争将公司发展成为我国介入医疗器械的主要生产基地和科研开发中心。
   

The Leading Chinese Developer of Interventional Medical Products

MicroPort is the leading Chinese developer, manufacturer, and marketer of innovative medical products for interventional cardiology and peripheral vascular diseases.

Since 1998, we assembled some of the very best talent in the medical device industry and set forth on a mission to develop superior medical technology for the interventional cardiology market. We were also determined to create affordable devices so that they would be accessible to people throughout China and emerging markets around the world.

Our initial success served as a foundation from which we are pioneering an expansive set of medical technologies. Under the leadership of a management team with extensive multinational medical experience, MicroPort is growing rapidly within and beyond our domestic region.

We are extending our solutions to Europe, Latin America, South America and other emerging markets. And we are working closely with physicians, hospitals, key opinion leaders, and government regulatory agencies to extend our technology throughout the world.

We represent the most extensive medical products company in one of the world’s largest countries. Our solid platform – including powerful R&D, vertically integrated manufacturing and worldwide distribution – is readily leveraged for new technologies and new markets. As we replicate our success in other regions, we are destined to become the first China-based, multinational medical product leader, bringing affordable products to people across the globe.